SMMT (Summit Therapeutics) Interest Expense: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SMMT Summit Therapeutics Inc SMMT
30 GF Score
Price $17.51
! 2 Warning Signs
View Full Analysis

What is Summit Therapeutics Interest Expense?

Summit Therapeutics SMMT +1.33% 30 Interest Expense is $0.00 Mil as of Jun. 2026. GuruFocus rates SMMT with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Summit Therapeutics's interest expense for the three months ended in Jun. 2026 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Summit Therapeutics's Operating Income for the three months ended in Jun. 2026 was $ -220.50 Mil. Summit Therapeutics's Interest Expense for the three months ended in Jun. 2026 was $ 0.00 Mil. GuruFocus does not calculate Summit Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Summit Therapeutics  (NAS:SMMT) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Summit Therapeutics's Interest Expense for the three months ended in Jun. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Jun. 2026 was $-220.50 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was $16.83 Mil.

Summit Therapeutics's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

GuruFocus does not calculate Summit Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Summit Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Summit Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Summit Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Summit Therapeutics Interest Expense Chart

Summit Therapeutics Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.24 -4.40 -16.46 -8.69 0.00

Summit Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SMMT
30GF Score
Summit Therapeutics Inc SMMT
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Summit Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $0.00 Mil mean?
Summit Therapeutics (SMMT) has a Interest Expense of $0.00 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Summit Therapeutics and its competitors.
Is Summit Therapeutics' Interest Expense too high?
Summit Therapeutics' current Interest Expense is $0.00 Mil. Overall, Summit Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Summit Therapeutics' Interest Expense compare to TECH and AXSM?
Summit Therapeutics' Interest Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Summit Therapeutics and its competitors. Summit Therapeutics's current Interest Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Summit Therapeutics stock overvalued right now?
Summit Therapeutics (SMMT) has a current Interest Expense of $0.00 Mil. The current Interest Expense is $0.00 Mil. Summit Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Summit Therapeutics (SMMT), the current Interest Expense is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Summit Therapeutics Business Description

Other Exchanges SMMT:Mexico
Address 601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
30GF Score

Get the complete analysis for SMMT

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.51
Price